J. Hartleib-Geschwindner

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone

U. Johansson, K. Bamberg, R. Jansson-Löfmark, 2019, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

U. Johansson, F. Jaisser, S. Geschwindner, 2018, PloS one.

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

K. Nelander, F. Erlandsson, K. Bamberg, 2018, British journal of clinical pharmacology.

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

R. Unwin, H. Ericsson, P. Forte, 2019, Clinical and translational science.

micein skeletal muscle of adenylate kinase-deficient Contraction-mediated phosphorylation of AMPK is

F. Bontemps, J. Zierath, M. Rider, 2015 .

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice

F. Jaisser, F. Foufelle, Ixchel Lima-Posada, 2022, Frontiers in Physiology.

Overexpression of AMP‐metabolizing enzymes controls adenine nucleotide levels and AMPK activation in HEK293T cells

F. Bontemps, M. Rider, L. Hue, 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

K. Bamberg, I. Squire, P. Greasley, 2022, Clinical and translational science.